ArticleBMC cancer2025
Low-dose radiotherapy combined with chemoimmunotherapy yields superior survival outcomes compared with chemoimmunotherapy alone for patients with small cell lung cancer with liver metastasis: a retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Application of Low-Dose Radiotherapy Combined with Immunotherapy for Drug-Resistant Hepatic Metastasis: a Case Series Analysis.Clinical and translational radiation oncology · 2027Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundLow-dose radiotherapy (LDRT) is a localized irradiation technique that utilizes a relatively low radiation dose, typically ranging from 1 to 5 Gy, which is significantly lower than the dose of 20-60 Gy administered in conventional radical radiotherapy. Chemoimmunotherapy (CIT) is a combined therapeutic approach that integrates chemotherapy and immunotherapy, aiming to improve antitumor efficacy through the synergistic interaction of both modalities. This retrospective study aimed to evaluate the survival outcomes of LDRT combined with CIT vs. CIT alone among small cell lung cancer (SCLC) patients with liver metastasis (LM).
methodsThis retrospective analysis included 74 SCLC patients with LM from our hospital between September 1, 2019 and September 1, 2024. The 74 included patients were divided into two groups: the CIT group and the LDRT + CIT group. Kaplan-Meier analysis was used to estimate the progression-free survival (PFS) and overall survival (OS). Subgroup analyses based on the line of therapy and the number of metastatic organs were also performed via univariate Cox proportional hazards regression analysis.
resultsThe results revealed that the median PFS of the LDRT + CIT group was longer than that of the CIT group (5.1 months vs. 4.0 months, p = 0.016), and the beneficial effects of LDRT + CIT on PFS were observed across multiple subgroups. Most subgroups did not exhibit improvements in OS. However, when the patients were stratified on the basis of line of therapy, the median OS (11.0 months vs. 6.0 months, p = 0.047) improved in the LDRT + CIT group receiving later-line treatment.
conclusionAmong SCLC patients with LM, LDRT + CIT may yield superior survival outcomes compared with CIT alone, particularly when LDRT is administered in later-line therapy and among specific subgroups. The findings of this study offer new treatment options for improving survival and quality of life in this challenging patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.